Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
24/05/2023 11:51
May 24 (Reuters) - Apexigen Inc APGN.O :
* PYXIS ONCOLOGY TO ACQUIRE APEXIGEN
* PYXIS ONCOLOGY INC - PROPOSED DEAL FOR TOTAL ENTERPRISE
VALUE OF
APPROXIMATELY $16 MILLION
* PYXIS ONCOLOGY INC - ALL-STOCK DEAL ALLOWS PYXIS ONCOLOGY
TO
MAINTAIN CASH RUNWAY INTO 1H 2025; PYX-201 AND PYX-106 REMAIN ON
TRACK
* PYXIS ONCOLOGY INC - WILL ACQUIRE APEXIGEN IN AN ALL-STOCK
TRANSACTION FOR IMPLIED VALUE OF $0.64 PER APEXIGEN SHARE
* PYXIS ONCOLOGY INC - PYXIS ONCOLOGY EXPECTS TO ISSUE
APPROXIMATELY 4.4 MILLION SHARES OF ITS COMMON STOCK TO APEXIGEN
STOCKHOLDERS TO ACQUIRE APEXIGEN
* PYXIS ONCOLOGY INC - UPON CLOSING OF BUSINESS COMBINATION,
APEXIGEN WILL BECOME A WHOLLY OWNED SUBSIDIARY OF PYXIS ONCOLOGY
* PYXIS ONCOLOGY INC - POST CLOSE, EXISTING PYXIS ONCOLOGY
LEADERSHIP TEAM WILL CONTINUE TO BE RESPONSIBLE FOR ALL
EXECUTIVE POSITIONS
Source text for Eikon: ID:nGNX4dxfBB
Further company coverage: APGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apexigen
See all newsBrief: Apexigen Inc - On August 15, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq